Global Markets for Orphan Drugs: PHM038C

Global Markets for Orphan Drugs

Report Code: PHM038C

Publish Date: May 2010

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

Worldwide, the orphan drug market reached $84.9 billion in 2009. The market is expected to grow at a compound annual growth rate (CAGR) of nearly 6% to reach $112.1 billion by 2014. The U.S. accounted for 51% of the market in 2009 and is expected to grow at a CAGR of 8.9% to reach $65.9 billion by 2014.
Biologic drugs accounted for a major share (64.3%) of the orphan drug market with sales of $54.6 billion in 2009, up from $51.4 billion in 2008. The size of the biologic orphan drug market is projected to grow at a 6.9% CAGR to reach $76.2 billion by 2014.
Orphan drugs for the cancer sector generated the largest amount of revenues, $30.6 billion in 2009, accounting for 36% of the market. Revenues for cancer-related orphan drugs are expected to grow at a CAGR of 10% to reach $49.7 billion in 2014.

INTRODUCTION

STUDY GOAL AND OBJECTIVES

The orphan drug industry has come a long way since its implementation, leaving many noticeable benchmarks along the way as the U.S. Orphan Drug Act (ODA), which was implemented in 1983, entered its 26^th year in 2009. The purpose of this report is to analyze the orphan drug industry and provide market, technology, and revenue forecasts for the period 2009 to 2014. The report also analyzes the influence of the orphan drug industry in the development of the biotechnology industry.

This BCC report provides an in-depth look at orphan drugs that had sales of more than $200 million in 2009. Future growth prospects of these drugs as well as the therapeutic areas of these drugs in general have been analyzed based on the market dynamics and regulatory factors. Life stories of blockbuster orphan drugs are tracked and analyzed in detail, recognizing various factors that played key roles in their success. Regional analysis of the industry in terms of current and future trends of the orphan drug market in important regions has been presented. The report also provides revenues of leading orphan products, identifies key market players with significant market shares, analyzes current and future strategies of these companies that will have an impact in the market, and, finally, analyzes the rare diseases that are being addressed by the industry and the broad therapeutic areas that these diseases represent and their future growth trends.

This report also analyzes the current and possible future legislation affecting development and marketing of orphan drugs in the U.S. and other countries and examines the influence of the Orphan Drug Act in the development of the biotech industry. The impact of developments in pharmacogenomics in the orphan drug industry is also analyzed. The rising influence of ODA in business strategy development of pharmaceutical companies, which is driving the emergence of innovative business strategies and approaches, is also analyzed in detail. Issues such as the impact of market exclusivity in drug pricing, affordability, and healthcare insurance are also analyzed. Finally, technology trends analysis has been presented in the report, identifying how the most prevalent technologies in the market have changed over the past decade with the advent of biotech companies and future growth trends.

REASONS FOR DOING THE STUDY

BCC published comprehensive reports on the orphan drug industry in 2004, and in 2007. The emerging trends identified in 2007 have become more established during the past 3 years. Moreover, new trends are emerging as big pharma realizes the failing of blockbuster business model. The role of biotechnology industry in the pharmaceutical market has become more prominent, which is reflected in the orphan drug sector as well.

The changing regulatory landscape of the industry and its effect in driving the growth is obvious and has been pointed out in the earlier BCC report, PHM038B, published in 2007. During the past 3 years, the role of regulators in deciding the future of the sector has become more prominent. Globally, awareness about rare diseases has increased, while the importance of ODA has received rising recognition. Following the example of the U.S. Food and Drug Administration’s (FDA’s) Orphan Drug Act, similar legislation — such as Singapore’s Orphan Drug Exemption to the Medicines Act and Japan’s Orphan Drug Amendment to the Pharmaceutical Affairs Law — has been developed by many other countries. This has opened new markets for companies involved in orphan drug development. The number of orphan drugs that have become blockbusters has also gone up. In 2006, there were 19 orphan drugs with sales of more than $1 billion. In 2009, this increased to 27.

The change in the attitude of the pharmaceutical industry towards orphan drugs is becoming more prominent. Business deals involving big pharmaceutical companies and small companies with a pipeline of orphan drug designations have increased lately, indicating the rising importance of orphan-drug-based business strategies in the pharmaceutical industry. Such new trends are changing the landscape of the entire pharmaceutical industry. This report analyzes the current and emerging trends in the market. The report also analyzes affordability issues. Rising prices of orphan drugs and the reluctance of insurance agencies to cover orphan drugs that are priced extremely high are two issues being taken seriously by governments and patient support groups. Various business models are being suggested and being designed to tackle these issues. This report analyzes these rising business models in detail.

INTENDED AUDIENCE

This study provides insight on successful regulatory strategies that helped orphan drugs become blockbusters. Valuable insights on various business models that take advantage of ODA incentives are also provided. In addition, emerging regulatory strategies in key markets for improving the affordability of orphan drugs by patients are included.

The key therapeutic categories that are getting high attention from the developers and the rare indications within these therapeutic areas that have benefited from ODA are identified. Business strategies that helped big pharmaceutical companies as well as biotech companies to enter the market as well as maintain their market shares have been identified. These detailed analyses are targeted to help strategy developers and decision makers of biotech and pharmaceutical companies. It also gives insights into the incentives that have been attractive for different segments of the industry. This is especially suitable for legislators involved in government policy development programs. Technology trend analysis gives an overview of successful technologies, which are helpful for research managers in charge of project identification and development.

SCOPE OF REPORT

This report contains:

An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends
Detailed discussion of successful orphan products
Global sales projections through 2014 for as many as 57 orphan drugs with sales exceeding $200 million
Key players in the market and their market shares
Detailed analysis of blockbuster orphan drugs
Analysis of the Orphan Drug Act and its influence in the growth of the biotech industry
The rising influence of pharmacogenomics in the orphan drug market
A discussion of specific rare diseases for which orphan drugs exist
Analysis of the most promising therapeutic areas in the industry and leading orphan drugs in these therapeutic areas
An outline of legislation and regulation, including public and private agencies involved in support and development
Technology trends analysis within the orphan drug market
In-depth analysis of leading companies and their successful strategies within the orphan drug market segment.

INFORMATION SOURCES AND METHODOLOGY

The base year of this study is 2009. The market size reflects the global revenues of drugs with orphan drugs status in the United States that have generated more than $200 million in revenues in 2009. Drugs with market exclusivity active during the base year as well as those with expired market exclusivities in the U.S. market are included. The sales represent total revenues, which include the sales for rare diseases as well as other indications. This approach is important since the objective of this report is to identify the significance of ODA in the growth of the orphan drugs segment. Regulatory incentives provided by ODA have helped to promote clinical trials of existing drugs to identify their effectiveness for several rare indications in addition to the emergence of companies with exclusive orphan-drug-based business models.

Market figures are based on revenues at the manufacturer level and are projected at 2009 dollar values (i.e., inflation is not computed into the projection figures). Forecasts are mainly based on the projections of the marketers. Growth of competing drugs, patient population, patent and market exclusivity status, and life cycle management strategies adopted by marketers have also been considered for estimating the future growth trends.

The information and data to prepare this study were derived from regulatory agencies, trade literature, patient support groups, annual reports of companies, and industry-related databases. The analysis presented are based on an extensive survey of the pharmaceutical industry as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, and national and world health organizations. Key information from the literature was used to obtain expert opinion and insights on commercial potential and market sizes from industry professionals, academic researchers, and government agency spokespersons.

AUTHOR’S CREDENTIALS

Syamala Ariyanchira is actively involved in technology assessment, strategic planning, competitor analysis, due diligence, and market analysis. She combines her technical background with business sector issues with ease. Her clients include investment firms, government agencies, and chemical and pharmaceutical companies. She holds a PhD from the Indian Institute of Science in Bangalore, India, and has more than 15 years of experience in the industry.

BCC ONLINE SERVICES

BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:

Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

Title/Chapter Name	Pages	Member Price
Full Report: Global Markets for Orphan Drugs	205	Free
Chapter- 1: INTRODUCTION	5	Free
STUDY GOAL AND OBJECTIVES REASONS FOR DOING THE STUDY INTENDED AUDIENCE SCOPE OF REPORT INFORMATION SOURCES AND METHODOLOGY AUTHOR’S CREDENTIALS RELATED REPORTS FROM BCC RESEARCH BCC ONLINE SERVICES DISCLAIMER
Chapter- 2: SUMMARY	2	Free
Table Summary : GLOBAL ORPHAN DRUGS DEMAND BY VALUE, THROUGH 2014 Figure Summary : GLOBAL ORPHAN DRUGS DEMAND BY VALUE, 2008-2014
Chapter- 3: OVERVIEW	23	Free
DEFINITION OF AN ORPHAN DRUG HISTORY OF ORPHAN DRUG LEGISLATION INCENTIVES FOR ORPHAN DRUG DEVELOPMENT THE NEED FOR INCENTIVES APPLICATIONS FOR ORPHAN DRUG DESIGNATIONS HAVE DOUBLED PROFITABILITY OF ORPHAN DRUGS CHALLENGES FOR EFFECTIVE USE OF THE ODA MARKET EXCLUSIVITY VERSUS PATENT PROTECTION MARKET SIZE AND KEY PLAYERS THE ORPHAN DRUG ACT - A BONUS FOR BIOTECH BIG PHARMA IS ENTERING THE ORPHAN DRUGS SECTOR AGGRESSIVELY CONCERNS ABOUT THE ORPHAN DRUG ACT COST-EFFECTIVENESS PRICING OF ORPHAN DRUGS ACCESS TO ORPHAN DRUGS AND REIMBURSEMENT - CURRENT PRACTICES INNOVATIVE APPROACHES OF PRICING AND REIMBURSEMENT HOW EFFECTIVE ODA IS IN PROMOTING RESEARCH ON RARE DISEASES? ORPHAN DRUGS-BASED BUSINESS MODELS — CASE STUDIES
Chapter- 4: WORLDWIDE INDUSTRY STRUCTURE	11	Free
GLOBAL AND REGIONAL SALES OF ORPHAN DRUGS INDUSTRY TRENDS BY SPONSOR TYPES ORPHAN DRUG REVENUES BY SPONSOR TYPES ORPHAN DRUGS - NOW A STRATEGIC CHOICE FOR THE PHARMA INDUSTRY LEADING PLAYERS IN THE GLOBAL ORPHAN DRUG MARKET
Chapter- 5: PRODUCTS	46	Free
ORPHAN DRUGS APPROVED BY THE U.S. FDA (1983 – 2009) ORPHAN DRUG DESIGNATIONS AND APPROVALS SINCE 1983 ORPHAN DRUGS WITH SALES EXCEEDING $200 MILLION IN 2009 DETAILED ANALYSIS OF SUCCESSFUL AND PROMISING ORPHAN DRUGS ORPHAN DRUG SALES BY TECHNOLOGY
Chapter- 6: APPLICATIONS	66	Free
CANCER CANCER-RELATED CONDITIONS CARDIOVASCULAR DISEASES AND BLOOD DISORDERS GASTROINTESTINAL DISEASES GENETIC DISEASES AND DISORDERS IMMUNE DISEASES INFECTIOUS DISEASES INFLAMMATORY DISEASES NEUROLOGICAL DISEASES AND DISORDERS REPRODUCTIVE DISEASES AND DISORDERS RESPIRATORY DISEASES OTHER SELECTED RARE DISEASES AND DISORDERS FOR WHICH ORPHAN PRODUCTS ARE AVAILABLE THERAPEUTIC AREAS WITH THE HIGHEST REVENUES FROM ORPHAN DRUGS IN 2009 AND THEIR FUTURE GROWTH PROSPECTS
Chapter- 7: LEGISLATION AND REGULATORY ENVIRONMENT	29	Free
LEGISLATION IN THE U.S. LEGISLATION - EUROPEAN UNION CONVERGENCE OF REGULATORY PRACTICES OF EMEA AND FDA FOR ORPHAN DRUG APPROVALS – AN EMERGING TREND LEGISLATION - JAPAN LEGISLATION - AUSTRALIA LEGISLATION - SINGAPORE LEGISLATION STATUS - OTHER COUNTRIES/REGIONS LEGISLATION COMPARISON - SUMMARY CALL FOR MODIFICATIONS OF ORPHAN DRUG LEGISLATION CORRELATION BETWEEN MARKET EXCLUSIVITY AND THE HIGH PRICE OF ORPHAN DRUGS IMPACT OF BIOSIMILARS ON THE ORPHAN DRUGS SECTOR
Chapter- 8: TECHNOLOGY TRENDS ANALYSIS	8	Free
PATENT ANALYSIS LEADING ORPHAN DRUGS AND RELATED PATENTS TECHNOLOGY TRENDS ANALYSIS BASED ON ORPHAN DRUG APPROVALS CONCLUSIONS OF TECHNICAL TRENDS ANALYSIS
Chapter- 9: C. CRAMER & CO. GMBH	12	Free
ABBOTT ACTELION PHARMACEUTICALS AMGEN INC. BAYER AG BIOGEN IDEC INC. CELGENE CORPORATION ELI LILLY AND CO. GENZYME CORPORATION F. HOFFMANN-LA ROCHE LTD. JOHNSON & JOHNSON SERVICES INC. NOVARTIS AG MERCK & CO. INC. PFIZER INC.
Chapter- 10: GLOSSARY	3	Free
Table 81 : GLOSSARY

Published - Sep-2007| Analyst - Syamala Ariyanchira| Code - PHM038B

Report Highlights

The global orphan drugs market reached $58.7 billion in 2006, growing by 8% from $54.5 billion in 2005. It is expected to grow at a compounded annual growth rate (CAGR) of 7% to reach $81.8 billion by 2011.
Regionally, U.S. revenues in the market grew to $32.5 billion accounting for 55% of the market in 2006. The U.S. market is expected to grow at a CAGR of 8% to reach $47.8 billion by 2011.
Biologic drugs account for over 60% of the orphan drug market with sales of $35.3 billion in 2006, up from $30.2 billion in 2005. The market size of biologic orphan drugs is projected to grow at a 9% CAGR to reach $53.4 billion by 2011.

Published - Feb-2004| Analyst - Lynn Gray| Code - PHM038A

Report Highlights

The total worldwide market for orphan drugs, including sales for nonorphan applications, exceeded $28 billion in 2003.
This market is expected to rise at an AAGR (average annual growth rate) of 9.1% to reach $43.6 billion in 2008.
As a percentage of overall global drug sales, orphans are expected to increase their share from 7.0% in 2003 to 7.5% in 2008, as growth of the orphan market outpaces that of the total market.
As of mid-2003, 221 orphan drugs had been developed for the treatment of rare diseases affecting about 11 million patients.
Some orphan products have sales in excess of $1 billion annually.

Recent Reports
Top Trending Reports

Related Reports

Recent Reports

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Active Pharmaceutical Ingredients: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM200C

The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Global Market for Contract Research Organization (CRO) Services

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM186C

The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Global Oncology Pharmaceuticals Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM256B

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

Excipients in Pharmaceuticals: Global Markets to 2029

Published - Sep 2024 | Publisher - Gundreddy Gopinadh | Code - PHM010M

The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

FAQ

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More

Global Markets for Orphan Drugs

Report Highlights

Table of Contents

Report Highlights

Report Highlights

Related Reports

Recent Reports

Top Trending Reports

Become A Member

Custom Consulting

Scorecard

Innovation Spotlight